» Articles » PMID: 10451704

Frequent Mutations of NF2 and Allelic Loss from Chromosome Band 22q12 in Malignant Mesothelioma: Evidence for a Two-hit Mechanism of NF2 Inactivation

Overview
Date 1999 Aug 19
PMID 10451704
Citations 36
Authors
Affiliations
Soon will be listed here.
Abstract

We previously reported NF2 mutations in malignant mesothelioma (MM) cell lines and corresponding primary tumors. We have now generated polyclonal antibodies that specifically recognize the C-terminus of the NF2 protein. Western blot analysis was performed on 25 MM cell lines, 14 of which showed no NF2 expression. Single-strand conformation polymorphism and DNA sequence analyses revealed NF2 mutations in each of these 14 cell lines. To explore the mechanism of inactivation of NF2, loss of heterozygosity analysis was performed with two microsatellite markers located in the vicinity of the NF2 locus in chromosome band 22q12. Eighteen of the 25 cell lines (72%) showed losses at one or both loci tested. All cases exhibiting mutation and/or aberrant expression of NF2 showed allelic losses, suggesting that inactivation of NF2 in MM occurs via a two-hit mechanism.

Citing Articles

NF2: An underestimated player in cancer metabolic reprogramming and tumor immunity.

Xu D, Yin S, Shu Y NPJ Precis Oncol. 2024; 8(1):133.

PMID: 38879686 PMC: 11180135. DOI: 10.1038/s41698-024-00627-5.


Inflammation as a chemoprevention target in asbestos-induced malignant mesothelioma.

Kadariya Y, Sementino E, Shrestha U, Gorman G, White J, Ross E Carcinogenesis. 2022; 43(12):1137-1148.

PMID: 36355620 PMC: 10122428. DOI: 10.1093/carcin/bgac089.


Clinical and molecular validation of BAP1, MTAP, P53, and Merlin immunohistochemistry in diagnosis of pleural mesothelioma.

Chapel D, Hornick J, Barlow J, Bueno R, Sholl L Mod Pathol. 2022; 35(10):1383-1397.

PMID: 35459788 PMC: 9529776. DOI: 10.1038/s41379-022-01081-z.


Inactivation of p21-Activated Kinase 2 (Pak2) Inhibits the Development of Nf2-Deficient Tumors by Restricting Downstream Hedgehog and Wnt Signaling.

Sementino E, Kadariya Y, Cheung M, Menges C, Tan Y, Kukuyan A Mol Cancer Res. 2022; 20(5):699-711.

PMID: 35082167 PMC: 9081258. DOI: 10.1158/1541-7786.MCR-21-0837.


Malignant pleural mesothelioma: an update.

Hajj G, Cavarson C, Pinto C, Venturi G, Navarro J, Cordeiro de Lima V J Bras Pneumol. 2021; 47(6):e20210129.

PMID: 34909922 PMC: 8836658. DOI: 10.36416/1806-3756/e20210129.